Recombinant Mouse PAP and Its Antinociceptive Effects
Author Information
Author(s): Sowa Nathaniel A., Vadakkan Kunjumon I., Zylka Mark J.
Primary Institution: University of North Carolina, Chapel Hill
Hypothesis
Does recombinant mouse prostatic acid phosphatase (mPAP) have antinociceptive properties similar to human and bovine PAP?
Conclusion
Recombinant mPAP has long-lasting antinociceptive effects that are dependent on A1-adenosine receptor activation.
Supporting Evidence
- Recombinant mPAP was shown to dephosphorylate AMP and ADP at neutral and acidic pH.
- A single injection of mPAP produced antinociceptive effects lasting three days.
- Antinociceptive effects were blocked by the A1R antagonist CPX, indicating receptor dependence.
- mPAP's effects were compared to those of human and bovine PAP, showing species conservation.
Takeaway
The study shows that a special protein from mice can help reduce pain for a long time, just like similar proteins from humans and cows.
Methodology
The study involved purifying recombinant mPAP and testing its effects on pain sensitivity in mice using various pain models.
Limitations
The study primarily focused on animal models, which may not fully translate to human conditions.
Participant Demographics
C57BL/6 male mice, 2–4 months old.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website